Preliminary Analysis Of A Phase Ii, Multicenter, Randomized, Active-Control Study To Evaluate The Efficacy And Safety Of Eganelisib (Ipi 549) In Combination With Nivolumab Compared To Nivolumab Monotherapy In Patients With Advanced Urothelial Carcinoma.

Piotr Tomczak,Lazar Popovic,Philippe Barthelemy, Aleksander Janicic, Elena Sevillano Fernandez, Delphine Borchiellini,Massimo Aglietta,José Maroto,Aurelien Carnot,Brenda O'Connell,Nora Zizlsperger, Halle Huihong Zhang,Begoña P. Valderrama

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 8|浏览16

暂无评分

摘要

436Background: Inhibition of the PD-1 pathway has demonstrated clinical benefit in metastatic urothelial carcinoma (mUC); however, response rates of 15% to 29% highlight the need for more effective...

查看译文

关键词

nivolumab monotherapy,advanced urothelial carcinoma,efficacy,eganelisib,active-control

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要